Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metronomic Oral Cyclosphosphamide as Third-line Systemic Treatment or Beyond in Patients With Inoperable Locoregionally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT02794077 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT02794077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02794077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metronomic Oral Cyclosphosphamide as Third-line Systemic Treatment or Beyond in Patients With Inoperable Locoregionally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2016
Enrollment
56 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent nasopharyngeal undifferentiated carcinoma, stage iv nasopharyngeal undifferentiated carcinoma